Skip to main content

Palto Therapeutics receives 150,000 Swiss francs from Venture Kick

| News

Palto Therapeutics receives 150,000 Swiss francs from Venture Kick


Allschwil-based Palto Therapeutics has won the third stage of the Venture Kick promotional funding program. As such, the company now stands to benefit from 150,000 Swiss francs in startup funding to support the further development of its RNA-based cancer therapy program.

The Venture Kick jury has named Palto Therapeutics from Allschwil in the canton of Basel-Landschaft as the winner of the third stage of the promotional funding program. Venture Kick winners are each entitled to receive an investment of 850,000 Swiss francs from the Kickfund as well as an InnoBooster grant totaling a further 150,000 Swiss francs. Palto Therapeutics was also supported by the Venture Mentoring program, which is operated by the investment and innovation promotion agency Basel Area Business & Innovation.

The innovation of the Allschwil-based startup consists of the development of a nanostructure known as SmartCoat. This precise and cost-effective technology can protect, traffic and target small interfering RNAs (siRNAs) to cancer cells. The technology can also be applied to other therapies that involve directly targeting therapeutically valuable molecules within diseased cells.

Expanding collaborations with partners

SmartCoat is “revolutionizing treatments for cancer and beyond”, as Venture Kick writes in a press release. The initiative for the promotion of startups also highlights its ambition of “making a meaningful impact in the current revolution of genetic medicine”.

According to the press release, Palto Therapeutics will put the 150,000 Swiss francs towards advancing the latest generation of its SmartCoat design and expanding collaborations with industrial partners. The next milestones are centered around “raising substantial seed financing in 2024”, with the aim of completing all non-clinical work to facilitate the start of the clinical trial.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Paradigm shift in pain management

Pain is a crucial sensation for survival, but it can also drive us to depression and long-term suffering if not...
Read More

BOOM Summit in Basel accelerates health technology

The BOOM Summit at Messe Basel in April 2024 will be a completely new kind of healthcare conference. The first...
Read More

Investors stump up 3.7 million Swiss francs in Onena Medicines

Onena Medicines has secured an investment of 3.7 million Swiss francs. The portfolio company of the biotech startup incubator BaseLaunch...
Read More

Do you have a question? We'd like to hear from you.